Indian pharmaceutical company Lupin announced on Monday that it has secured approval from the US Food and Drug Administration (USFDA) to introduce a generic HIV medication to the American market. The ...

Lupin receives tentative USFDA approval for its generic HIV treatment, combining Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. The drug, equivalent to Janssen's Symtuza ...

In the past two days, Lupin stock has surged 8 per cent after the pharmaceutical company received tentative approval from the US Food and Drug Administration (USFDA) to market generic HIV combination ...

The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...

According to IQVIA MAT December 2024, this drug will generate a U.S. market sales revenue of $1,374 million. Lupin is the first-to-file applicant for this generic product. Being the first-to-file ...

Credit: Shidlovski/Shutterstock. The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and Valsartan tablets for heart failure ...

Lupin has received USFDA approval to market a generic HIV medication in the US market, under the PEPFAR program. The drug will be manufactured in Nagpur and supplied to low-and middle-income countries ...

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US ...

Mumbai: Global pharma major, Lupin Limited, has announced that the Company has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug ...

"The tentative approval from the USFDA for our Abacavir, Dolutegravir and Lamivudine Tablets enables us to improve the well-being of pediatric patients with HIV-1, thereby significantly boosting our ...

Lupin gained 3.66% to Rs 2,188 after the company announced that it has received a tentative approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Darunavir, Cobicistat, ...